Idis Named Patient Programme Pre-approval

Partnering with Idis at any stage of your product’s clinical development will:

• Enable you to meet early access requests from healthcare professionals and patients
• Allow you to collaborate with key opinion leaders and specialists, helping you to establish and run the programme alongside your clinical development programme
• Ensure that all access requests are managed by Idis through until your product's launch and beyond
• Provide you with consolidated information which can be used to mitigate future risks

Our world is growing increasingly connected and investigational drugs are no longer hidden from the public until they’re ready for general use. Requests for developmental drugs are growing, putting pharmaceutical and biotech companies under increasing pressure. It’s important to be ready with a programme that ensures an appropriate response to these requests.

By partnering with us to develop an Idis Named Patient Programme Pre-approval we can help you do just that ethically and reliably, while ensuring appropriate training and education, and ensuring that vital feedback is delivered directly to you.

An Idis Named Patient Programme Pre-approval will help you minimise any risks associated with early access outside of the controlled environment of a clinical trial, while giving you invaluable information about how your drug performs and is used in a real-world setting.

As market leaders in our field we're highly experienced in managing programmes for a diverse range of drugs in many different therapeutic areas. In particular, we have extensive knowledge in the area of oncology. In fact, no other company has launched more oncology products than Idis.

By consulting with Idis, you can rest assured that whatever your needs and whatever your therapeutic area, we will have a solution to suit you.

Idis Named Patient Programmes are regulatory compliant in all countries. We have the consultancy expertise to design and create even the most complex programmes and we take care of every regulatory detail, ensuring peace of mind.

We also provide expert advice in countries where the regulatory infrastructure is less well defined.